Sign of a new delivery system for levodopa coming down the pike?
or potential to replace DBS?
Sign of a new delivery system for levodopa coming down the pike?
or potential to replace DBS?
fiercepharma.com/pharma/abb...
US approval delayed to 2024
ncbi.nlm.nih.gov/books/NBK5...
[US] "Treatment with Vyalev is expected to have an annual cost of $62,023 per patient assuming patients will use approximately 1 vial per day. "
Extortionate in my opinion for something that provides a more even flow of levodopa.